ライフサイエンスコーパス: mesalamine

1 secondary analyses indicated the efficacy of mesalamine.

2 t a novel antineoplastic molecular effect of mesalamine.

3 erative effects of TNF-alpha were blocked by mesalamine.

4 degradation of Ikappa-Balpha were blocked by mesalamine.

5 r, or ceramide in the presence or absence of mesalamine.

6 assess the noninferiority of delayed-release mesalamine 1.6-2.4 g/day administered once daily compare

7 Patients received mesalamine (1.2 g, 2.4 g, or 4.8 g) or placebo once dail

8 greater proportion of patients receiving MMX mesalamine 2.4 g/day given once daily (40.5%; P = .01) a

9 -to-moderate ulcerative colitis received MMX mesalamine 2.4 g/day or 4.8 g/day given once daily, ASAC

10 at were given budesonide MMX (9 mg or 6 mg), mesalamine (2.4 g, as reference), or placebo for 8 weeks

11 Short-term treatment with oral mesalamine (3 g once daily) appears to be ineffective.

12 omized 131 patients to receive 6-MP (50 mg), mesalamine (3 g), or placebo daily in a double-blind, do

13 Delayed-release mesalamine 4.8 g/day (800-mg tablet) is efficacious and

14 assess the noninferiority of delayed-release mesalamine 4.8 g/day (Asacol HD, 800-mg tablet; Procter

15 cted to determine the efficacy and safety of mesalamine 4.8 g/day compared with 2.4 g/day for the tre

16 Although mesalamine 4.8 g/day was not statistically different fro

17 rectal cancer, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and fola

18 The aim of this study was to investigate mesalamine, a standard therapy for inflammatory bowel di

19 tion, 43% of patients who received 4.8 g/day mesalamine achieved clinical remission at week 6 compare

20 placebo (P = .0006); 44.0% of patients given mesalamine achieved clinical remission, but budesonide w

21 f 389) of patients who received 4.8 g/day of mesalamine achieved treatment success at week 6, compare

22 No new adverse events were identified with mesalamine administration.

23 Although a protective role for mesalamine against colon cancer in ulcerative colitis ha

24 cell and biofilm formation, suggesting that mesalamine aids in diminishing the capacity of bacteria

25 In this report, we demonstrate that mesalamine, an anti-inflammatory aminosalicylate, dose-d

26 s achieved by 30.0% of patients treated with mesalamine and 20.6% of those given placebo, a differenc

27 luorescent dyes and commercial drugs such as mesalamine and doxorubicin, which eluted from the grippe

28 remission rates were 29.0% and 13.8% in the mesalamine and placebo groups, respectively (difference

29 In contrast, both mesalamine and sodium salicylate have been shown to lowe

30 s take drugs to reduce inflammation (such as mesalamine and steroids).

31 IEC-18 cells were treated with 0.3-3 mmol/L mesalamine and thermally stressed (39 degrees C-42 degre

32 95% CI, 61%-91%) in patients receiving 6-MP, mesalamine, and placebo, respectively.

33 rolled trials that compared the abilities of mesalamine, antibiotics, budesonide, immunomodulators, a

34 Although mesalamines are still often used to treat Crohn disease,

35 multicenter study to evaluate budesonide and mesalamine as short-term treatments for collagenous coli

36 fety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-d

37 at evaluated the efficacy of delayed-release mesalamine (Asacol 800-mg tablet) 4.8 g/day.

38 A delayed-release oral mesalamine (ASACOL; Procter & Gamble, Cincinnati, OH) re

39 Once-daily dosing of delayed-release mesalamine at doses of 1.6-2.4 g/day was shown to be as

40 Mesalamine augments thermal induction of the intestinal

41 colitis, the platform carrying budesonide or mesalamine becomes more viscoelastic near body temperatu

42 in nonepithelial cells, the possibility that mesalamine confers cell protection by increasing intesti

43 e results are consistent with the model that mesalamine contributes to chemoprevention in CAC by redu

44 Among patients treated with mesalamine delayed/extended-release tablets (Mezavant(R)

45 s in patients using maintenance therapy with mesalamine derivatives has been expanded.

46 Mesalamine did not reduce the rate of diverticulitis rec

47 Mesalamine did not reduce time to recurrence, and the pr

48 in human intestinal epithelial cells and if mesalamine directly interacts with PN or its precursor,

49 The efficacy of mesalamine does not appear to be strong data supported.

50 budesonide once daily, Budenofalk, n = 30), mesalamine granules (3 g mesalamine once daily, Salofalk

51 Although mesalamine had no effects on the basal hsp72 expression

52 Mesalamine has been proposed as a treatment option for c

53 Mesalamine has many effects and is commonly used for the

54 Mesalamine has shown efficacy in preventing relapse in i

55 We investigated the efficacy of mesalamine in preventing recurrence of diverticulitis in

56 The beneficial effects of mesalamine in the treatment of inflammatory bowel diseas

57 The practice of dosing mesalamines in divided doses for the treatment of ulcera

58 g Crohn's disease (e.g., corticosteroids and mesalamine); in fact, some medications are believed to b

59 Mesalamine inhibits TNF-alpha-mediated effects on intest

60 Mesalamine is a mainstay therapeutic agent in chronic ul

61 the role of anti-inflammatory treatment with mesalamine is being actively investigated.

62 Mesalamine is not recommended for this indication.

63 It is not clear what induction dose of mesalamine is optimal for treating patients with mildly

64 as beneficial as previously thought and that mesalamine might be useful.

65 Furthermore, a new 5-aminosalicylic acid (mesalamine MMX) has been released that effectively induc

66 MMX mesalamine offers effective and convenient mesalamine th

67 The effects of mesalamine on basal expression and the threshold and tim

68 Effects of mesalamine on epithelial proliferation and activation of

69 Effects of mesalamine on P-beta-catenin staining and function were

70 The effects of mesalamine on PN decomposition and NO half-life were det

71 f chemoprevention, we examined the effect of mesalamine on TC22 expression using LS180 colon cancer c

72 bowel disease, we investigated the effect of mesalamine on TNF-alpha-regulated signal transduction an

73 udenofalk, n = 30), mesalamine granules (3 g mesalamine once daily, Salofalk, n = 25), or placebo for

74 Mesalamine or sulfasalazine (2 mM), but not sulfapyridin

75 isits (OR, 2.0; 95% CI: 1.4-3.0), and use of mesalamine (OR, 2.8; 95% CI: 1.7-4.4).

76 al remission, but budesonide was superior to mesalamine (P = .0035).

77 Mesalamine protected the epithelial barrier function of

78 Mesalamine rapidly degraded PN, whereas the half-life of

79 reviously treated with corticosteroids, oral mesalamines, rectal therapies, or multiple UC medication

80 -10(-/-) and human colitis samples show that mesalamine reduced Akt activation and P-beta-catenin lev

81 In IL-10(-/-) mice, mesalamine reduced CID concordant with inhibition of cry

82 mens with severe inflammation suggested that mesalamine reduced P-beta-catenin levels in tissue refra

83 present study addressed the possibility that mesalamine reduces beta-catenin-associated progenitor ce

84 etwork meta-analysis, compared with placebo, mesalamine (relative risk [RR], 0.60; 95% credible inter

85 Derivatives of 5-aminosalicylic acid (mesalamine) represent a mainstay in inflammatory bowel d

86 Mesalamine resulted in a dose-dependent decrease in PN-i

87 (RR, 0.01; 95% CrI, 0.00-0.05), but neither mesalamine (RR, 0.67; 95% CrI, 0.39-1.08) nor budesonide

88 -beta-catenin levels in tissue refractory to mesalamine's anti-inflammatory effects.

89 Mesalamine serves as the gold standard in treating ulcer

90 ; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under

91 We conclude that mesalamine, sulfasalazine, and rosiglitazone significant

92 X mesalamine offers effective and convenient mesalamine therapy, potentially improving treatment comp

93 , patients were required to initiate an oral mesalamine treatment between January 2005 and December 2

94 Here, we show that mesalamine treatment rapidly decreases polyphosphate lev

95 tis (UC), little is known about adherence to mesalamine treatments and determinants that can predict

96 y was to assess adherence and persistence to mesalamine treatments and their potential determinants i

97 C exhibited low adherence and persistence to mesalamine treatments.

98 A sample of 1,681 of the new oral mesalamine users (mean age = 55.3) patients was obtained

99 lysis was conducted using a random sample of mesalamine users with UC.

100 high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) tech

101 uble-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcera

102 uated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent div

103 T29 cells were divided in several protocols: mesalamine was administered 2 hours before, simultaneous

104 nt decrease in PN-induced apoptosis, whether mesalamine was administered before (>10 micromol/L; IC50

105 Once-daily MMX mesalamine was efficacious and well-tolerated for the in

106 Mesalamine was found to inhibit IL-1-stimulated RelA pho

107 Mesalamine was not superior to placebo in preventing rec

108 ubjects given 9 mg or 6 mg budesonide MMX or mesalamine were 17.9%, 13.2%, and 12.1%, respectively, c

109 ubjects given 9 mg or 6 mg budesonide MMX or mesalamine were 28.5%, 28.9%, and 25.0%, respectively, c

110 atients given 9 mg or 6 mg budesonide MMX or mesalamine were 33.3%, 30.6%, and 33.9%, respectively, c

111 ubjects given 9 mg or 6 mg budesonide MMX or mesalamine were 41.5%, 35.5%, and 33.1%, respectively, c

112 e activation of MAP kinase were inhibited by mesalamine, whereas epidermal growth factor activation o

113 with the FDA-approved anti-inflammatory drug mesalamine, which has recently been shown to attenuate p

114 l was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical,